These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 26705678)
1. A Single-Center Experience With Brentuximab Vedotin in Gamma Delta T-Cell Lymphoma. Talpur R; Chockalingam R; Wang C; Tetzlaff MT; Duvic M Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):e15-9. PubMed ID: 26705678 [No Abstract] [Full Text] [Related]
2. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225 [TBL] [Abstract][Full Text] [Related]
3. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039 [TBL] [Abstract][Full Text] [Related]
5. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Gualberto A Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011 [TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin for the treatment of CD30+ lymphomas. Foyil KV; Bartlett NL Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188 [TBL] [Abstract][Full Text] [Related]
7. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247 [TBL] [Abstract][Full Text] [Related]
8. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Fanale MA; Forero-Torres A; Rosenblatt JD; Advani RH; Franklin AR; Kennedy DA; Han TH; Sievers EL; Bartlett NL Clin Cancer Res; 2012 Jan; 18(1):248-55. PubMed ID: 22080439 [TBL] [Abstract][Full Text] [Related]
9. [Brentuximab vedotin: new treatment for CD30+ lymphomas]. Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822 [TBL] [Abstract][Full Text] [Related]
10. CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity. Theurich S; Wennhold K; Wedemeyer I; Rothe A; Hübel K; Shimabukuro-Vornhagen A; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M Transplantation; 2013 Aug; 96(3):e16-8. PubMed ID: 23917689 [No Abstract] [Full Text] [Related]
11. Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression. Saintes C; Saint-Jean M; Renaut JJ; Dréno B; Quéreux G Br J Dermatol; 2015 Mar; 172(3):819-21. PubMed ID: 25113163 [No Abstract] [Full Text] [Related]
12. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. Oregel KZ; Everett E; Zhang X; Nagaraj G Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026 [TBL] [Abstract][Full Text] [Related]
13. Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. Zinzani PL; Corradini P; Gianni AM; Federico M; Santoro A; Vitolo U; Barosi G; Tura S Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):507-13. PubMed ID: 26195435 [TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate. Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550 [TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin in T-cell lymphoma. Van Der Weyden C; Dickinson M; Whisstock J; Prince HM Expert Rev Hematol; 2019 Jan; 12(1):5-19. PubMed ID: 30526166 [TBL] [Abstract][Full Text] [Related]
16. Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy. Sotomayor EM; Young KH; Younes A Clin Adv Hematol Oncol; 2014 Apr; 12(4 Suppl 10):1-22. PubMed ID: 24870054 [TBL] [Abstract][Full Text] [Related]
17. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. de Claro RA; McGinn K; Kwitkowski V; Bullock J; Khandelwal A; Habtemariam B; Ouyang Y; Saber H; Lee K; Koti K; Rothmann M; Shapiro M; Borrego F; Clouse K; Chen XH; Brown J; Akinsanya L; Kane R; Kaminskas E; Farrell A; Pazdur R Clin Cancer Res; 2012 Nov; 18(21):5845-9. PubMed ID: 22962441 [TBL] [Abstract][Full Text] [Related]